Levels of heroin and its metabolites in blood and brain extracellular fluid after i.v. heroin administration to freely moving rats

British Journal of Pharmacology

Volumn 170, Issue 3, 2013, Pages 546-556

  Gottas A ^a   Oiestad E L ^a   Boix, F ^a   Vindenes, V ^a   Ripel, A ^a   Thaulow, C H ^a   Morland J ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

acetylmorphine; CNS; distribution; heroin; metabolite kinetic; microdialysis; morphine; opioid; pharmacokinetic; prodrug

Indexed keywords

DIAMORPHINE; DRUG METABOLITE; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 ACETATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; EXTRACELLULAR FLUID; JUGULAR VEIN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ACETYLMORPHINE; CNS; DISTRIBUTION; HEROIN; METABOLITE KINETIC; MICRODIALYSIS; MORPHINE; OPIOID; PHARMACOKINETIC; PRODRUG;

ADMINISTRATION, INTRAVENOUS; ANALGESICS, OPIOID; ANIMALS; BIOTRANSFORMATION; BRAIN; CHROMATOGRAPHY, LIQUID; EXTRACELLULAR FLUID; HEROIN; MALE; MORPHINE DERIVATIVES; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; TANDEM MASS SPECTROMETRY;

EID: 84884566425     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12305     Document Type: Article

References (50)

1. Abbadie C, Pan YX, Pasternak GW, (2000). Differential distribution in rat brain of mu opioid receptor carboxy terminal splice variants MOR-1C-like and MOR-1-like immunoreactivity: evidence for region-specific processing. J Comp Neurol 419: 244-256.
2. Andersen JM, Ripel A, Boix F, Normann PT, Morland J, (2009). Increased locomotor activity induced by heroin in mice: pharmacokinetic demonstration of heroin acting as a pro-drug for the mediator, 6-monoacetylmorphine, in vivo. J Pharmacol Exp Ther 331: 153-161.
3. Anthony JC, Warner LA, Kessler RC, (1994). Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol 2: 244-268.
4. Anton B, Salazar A, Flores A, Matus M, Marin R, Hernandez JA, et al. (2009). Vaccines against morphine/heroin and its use as effective medication for preventing relapse to opiate addictive behaviors. Hum Vaccin 5: 214-229.
5. Avdeef A, Barrett DA, Shaw PN, Knaggs RD, Davis SS, (1996). Octanol-, chloroform-, and propylene glycol dipelargonat-water partitioning of morphine-6-glucuronide and other related opiates. J Med Chem 39: 4377-4381.
6. Bare LA, Mansson E, Yang DM, (1994). Expression of 2 variants of the human mu- opioid receptor messenger-Rna in Sk-N-Sh cells and human brain. FEBS Lett 354: 213-216.
7. Boix F, Andersen JM, Mørland J, (2013). Pharmacokinetic modeling of subcutaneous heroin and its metabolites in blood and brain of mice. Addict Biol 18: 1-7.
8. Everitt BJ, Robbins TW, (2005). Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 8: 1481-1489.
9. Feltenstein MW, See RE, (2008). The neurocircuitry of addiction: an overview. Br J Pharmacol 154: 261-274.
10. Gianutsos G, Cohen SD, Carlson G, Heyman R, Salva P, Morrow G, et al. (1986). Alteration of in vivo and in vitro effects of heroin by esterase inhibition. Toxicol Appl Pharmacol 82: 14-18.
11. Glatting G, Kletting P, Reske SN, Hohl K, Ring C, (2007). Choosing the optimal fit function: comparison of the Akaike information criterion and the F-test. Med Phys 34: 4285-4292.
12. Gottas A, Oiestad EL, Boix F, Ripel A, Thaulow CH, Pettersen BS, et al. (2012). Simultaneous measurement of heroin and its metabolites in brain extracellular fluid by microdialysis and ultra performance liquid chromatography tandem mass spectrometry. J Pharmacol Toxicol Methods 66: 14-21.
13. Hammarlund-Udenaes M, (2010). Active-site concentrations of chemicals-are they a better predictor of effect than plasma/organ/tissue concentrations? Basic Clin Pharmacol Toxicol 106: 215-220.
14. Hammarlund-Udenaes M, Friden M, Syvanen S, Gupta A, (2008). On the rate and extent of drug delivery to the brain. Pharm Res 25: 1737-1750.
15. Inturrisi CE, Schultz M, Shin S, Umans JG, Angel L, Simon EJ, (1983). Evidence from opiate binding studies that heroin acts through its metabolites. Life Sci 33 (Suppl. 1): 773-776.
16. Johnson SW, North RA, (1992). Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 12: 483-488.
17. Karinen R, Andersen JM, Ripel A, Hasvold I, Hopen AB, Morland J, et al. (2009). Determination of heroin and its main metabolites in small sample volumes of whole blood and brain tissue by reversed-phase liquid chromatography-tandem mass spectrometry. J Anal Toxicol 33: 345-350.
18. Kinsey BM, Jackson DC, Orson FM, (2009). Anti-drug vaccines to treat substance abuse. Immunol Cell Biol 87: 309-314.
19. 18F]cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther 295: 1070-1076.
20. Koob GF, Bloom FE, (1988). Cellular and molecular mechanisms of drug-dependence. Science 242: 715-723.
21. Ludden TM, Beal SL, Sheiner LB, (1994). Comparison of the Akaike information criterion, the Schwarz criterion and the F-test as guides to model selection. J Pharmacokinet Biopharm 22: 431-445.
22. National Institute on Drug Abuse (2005). Heroin abuse and addiction. National Institutes of Health. Available at: http://www.drugabuse.gov/ publications/research-reports/heroin-abuse-addiction (accessed 7/28/2013).
23. Oldendorf WH, Hyman S, Braun L, Oldendorf SZ, (1972). Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection. Science 178: 984-986.
24. Pan YX, Pasternak GW, (2011). Molecular biology of mu opioid receptors. In:, Pasternak GW, (ed.). The Opiate Receptors, 2nd edn. Springer: New York, pp. 121-160.
25. Pan YX, Xu J, Bolan E, Abbadie C, Chang A, Zuckerman A, et al. (1999). Identification and characterization of three new alternatively spliced mu-opioid receptor isoforms. Mol Pharmacol 56: 396-403.
26. Pan YX, Xu J, Bolan E, Chang A, Mahurter L, Rossi G, et al. (2000). Isolation and expression of a novel alternatively spliced mu opioid receptor isoform, MOR-1F. FEBS Lett 466: 337-340.
27. Pan YX, Xu A, Mahurter L, Bolan E, Xu MM, Pasternak GW, (2001). Generation of the mu opioid receptor (MOR-1) protein by three new splice variants of the Oprm gene. Proc Natl Acad Sci U S A 98: 14084-14089.
28. Pan YX, Xu J, Xu MM, Rossi GC, Matulonis JE, Pasternak GW, (2009). Involvement of exon 11-associated variants of the mu opioid receptor MOR-1 in heroin, but not morphine, actions. Proc Natl Acad Sci U S A 106: 4917-4922.
29. Pasternak GW, (2010). Molecular insights into mu opioid pharmacology from the clinic to the bench. Clin J Pain 26: S3-S9.
30. Pasternak GW, Bodnar RJ, Clark JA, Inturrisi CE, (1987). Morphine-6-glucuronide, a potent mu agonist. Life Sci 41: 2845-2849.
31. Paxinos G, Watson C, (1998). The Rat Brain in Stereotaxic Coordinates, 4th edn. Academic Press: San Diego, CA.
32. Pravetoni M, Raleigh MD, Le Naour M, Tucker AM, Harmon TM, Jones JM, et al. (2012). Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats. Vaccine 30: 4617-4624.
33. Probst RJ, Lim JM, Bird DN, Pole GL, Sato AK, Claybaugh JR, (2006). Gender differences in the blood volume of conscious Sprague-Dawley rats. J Am Assoc Lab Anim Sci 45: 49-52.
34. Rook EJ, Huitema AD, van den Brink W, Van Ree JM, Beijnen JH, (2006a). Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature. Curr Clin Pharmacol 1: 109-118.
35. Rook EJ, Van Ree JM, van den Brink W, Hillebrand MJX, Huitema ADR, Hendriks VM, et al. (2006b). Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. Basic Clin Pharmacol Toxicol 98: 86-96.
36. Rossi GC, Pan YX, Brown GP, Pasternak GW, (1995a). Antisense mapping the Mor-1 opioid receptor-evidence for alternative splicing and a novel morphine-6-beta-glucuronide receptor. FEBS Lett 369: 192-196.
37. Rossi GC, Standifer KM, Pasternak GW, (1995b). Differential blockade of morphine and morphine-6-beta-glucuronide analgesia by antisense oligodeoxynucleotides directed against Mor-1 and G-protein alpha-subunits in rats. Neurosci Lett 198: 99-102.
38. Rossi GC, Leventhal L, Pan YX, Cole J, Su W, Bodnar RJ, et al. (1997). Antisense mapping of MOR-1 in rats: distinguishing between morphine and morphine-6 beta-glucuronide antinociception. J Pharmacol Exp Ther 281: 109-114.
39. Samaha AN, Robinson TE, (2005). Why does the rapid delivery of drugs to the brain promote addiction? Trends Pharmacol Sci 26: 82-87.
40. Schlosburg JE, Vendruscolo LF, Bremer PT, Lockner JW, Wade CL, Nunes AA, et al. (2013). Dynamic vaccine blocks relapse to compulsive intake of heroin. Proc Natl Acad Sci U S A 110: 9036-9041.
41. Schuller AG, King MA, Zhang J, Bolan E, Pan YX, Morgan DJ, et al. (1999). Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. Nat Neurosci 2: 151-156.
42. Selley DE, Cao CC, Sexton T, Schwegel JA, Martin TJ, Childers SR, (2001). [mu] Opioid receptor-mediated G-protein activation by heroin metabolites: evidence for greater efficacy of 6-monoacetylmorphine compared with morphine. Biochem Pharmacol 62: 447-455.
43. Stowe GN, Schlosburg JE, Vendruscolo LF, Edwards S, Misra KK, Schulteis G, et al. (2011). Developing a vaccine against multiple psychoactive targets: a case study of heroin. CNS Neurol Disord Drug Targets 10: 865-875.
44. Strandberg JJ, Kugelberg FC, Alkass K, Gustavsson A, Zahlsen K, Spigset O, et al. (2006). Toxicological analysis in rats subjected to heroin and morphine overdose. Toxicol Lett 166: 11-18.
45. Umans JG, Inturrisi CE, (1981). Pharmacodynamics of subcutaneously administered diacetylmorphine, 6-acetylmorphine and morphine in mice. J Pharmacol Exp Ther 218: 409-415.
46. Umans JG, Inturrisi CE, (1982). Heroin: analgesia, toxicity and disposition in the mouse. Eur J Pharmacol 85: 317-323.
47. Volkow ND, Fowler JS, Wang GJ, Swanson JM, (2004). Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 9: 557-569.
48. Way EL, Kemp JW, Young JM, Grassetti DR, (1960). The pharmacologic effects of heroin in relationship to its rate of biotransformation. J Pharmacol Exp Ther 129: 144-154.
49. Xu J, Xu MM, Hurd YL, Pasternak GW, Pan YX, (2009). Isolation and characterization of new exon 11-associated N-terminal splice variants of the human mu opioid receptor gene. J Neurochem 108: 962-972.
50. Zimprich A, Simon T, Hollt V, (1995). Cloning and expression of an isoform of the rat mu-opioid receptor (Rmor1B) which differs in agonist-induced desensitization from Rmor1. FEBS Lett 359: 142-146.